Luoxin Pharmaceutical's revenue in the first quarter increased by 36.62%, and the full-year performance in the post-epidemic era can be expected

Luoxin Pharmaceutical released its 2020 annual report and 2021 quarterly report
.

The announcement shows that due to the epidemic, pharmaceutical companies have experienced varying degrees of delays in start-up, suspension of production, and transportation obstruction.

However, as the domestic epidemic has been clearly controlled, the market has gradually improved
.

The company's performance in the first quarter emerged from the impact of the epidemic and ushered in improvement

Focusing on the two major advantages of digestion and breathing, with strong certainty in performance

The growth core of the medical industry is still the development and product iteration based on the needs of patients
.

To obtain long-term development opportunities, companies must be guided by unmet clinical needs and continue to be driven by innovation

After years of accumulation, Luoxin Pharmaceutical has successfully established a market position in the digestion and respiratory fields, and reserves a comprehensive and competitive product portfolio
.

Adhering to the strategy of "Science and Technology", we will focus on areas of superiority and continue to consolidate our advantages and improve the competitiveness of our products

In the field of digestive products, the company's research and products on sale have covered mainstream indications in the digestive field
.

The representative product Lansoprazole for injection (trade name "Lanchuan") has added new indications to the scope of original indications, and has been approved for the creation of 3.

In the field of respiratory products, Luoxin Pharmaceutical also maintains a leading position
.

Ambroxol hydrochloride is currently the most widely used expectorant in clinical practice.

From realizing the replacement of original research with high quality and high price to the initiative to solve unmet clinical needs, Luoxin Pharmaceuticals not only continues to improve R&D and innovation capabilities and industrialization capabilities, but also pays more attention to drugs with clinical advantages in the world, relying on strong Clinical advancement capabilities, Chinese market channel advantages and strong commercialization capabilities have accelerated the development and listing of drugs in China
.

Driven by the "Healthy China 2030" policy and the country's continuous encouragement of innovation and development to accelerate the replacement of original research policy dividends, I believe that the company's development results will continue to appear in the future

       Independent research and development + cooperative research and development go hand in hand to accelerate the transformation of leading innovative drugs

       In addition to focusing on intensive products in advantageous areas, Luoxin Pharmaceutical has adopted a dual-track model of independent R&D and cooperative R&D to enhance R&D capabilities
.

According to the announcement, the company invested 463 million yuan in R&D in 2020, and the R&D investment ratio reached 7.

       In addition, the company has also strengthened the project management of new generic drugs and innovative drugs and the management of product portfolios, relying on the supply chain and business development to enhance the ability to obtain R&D product pipelines, and expand the cooperation and development of R&D pipelines with international companies in China.
The layout of preparation varieties with technical barriers will enable the company's performance growth and long-term development
.

       Luoxin Pharmaceutical said that the company mainly selects funds that focus on innovation at home and abroad and have a high professional reputation for investment or cooperation to deepen the company’s understanding and deployment of cutting-edge fields; on the other hand, the company will also directly invest in potential innovations Pharmaceutical companies, through investment incubation, gradually build an ecosystem composed of biotech start-ups, professional investment institutions, and large pharmaceutical companies
.
In the field of treatment, the company will continue to focus on the advantages of digestion and breathing, and introduce overseas clinical phase III or large varieties that have been marketed.
These varieties have been fully verified for overseas sales
.

       In terms of the pace of international cooperation, Luo Xin can be said to be an early entrant and layout player.
Judging from the current progress of the innovative drug research and development pipeline, the first cooperation project is about to usher in a harvest period
.
This also confirms the company's successful commercialization capabilities in the Chinese market and successful international cooperation experience
.
During the "Thirteenth Five-Year Plan" period, Luoxin Pharmaceutical has established in-depth cooperative relations with world-renowned companies such as JW Holdings in South Korea, Bausch Health Companies Inc.
in the United States, AstraZeneca, Arabindo Pharmaceutical Co.
, Ltd.
, YSLAB in France, and Imperial Pharmaceuticals.
, Focus on innovative layout in advantageous areas, with a view to filling the blank domestic market in China
.

       Take the third-generation three-chamber bag total parenteral nutrition product introduced last year containing fish oil as an example.
This product was signed and introduced by the company and South Korea JW Holdings, and has a domestic product market of nearly 5 billion
.
After the company obtains its exclusive development and commercialization rights in China, while consolidating its leading position in the digestion field, it can also create synergy with existing products.
It is expected that future performance will usher in a new round of growth
.

       Combined with the performance of Luoxin Pharmaceutical in the BD market in recent years, the company’s series of actions can show the determination to implement the innovation and transformation strategy.
In addition to accelerating the development of innovative product pipelines, it also actively introduces continuous optimization and optimization through cooperation at home and abroad.
Expanded the innovative product line and created a research and development strategy combining innovation and imitation
.
According to Wind data, as of April 27, the price-earnings ratio of the generic drug index (8841087.
WI) was 38.
9 times, and the price-earnings ratio of the innovative drug index (8841049.
WI) was 55.
9 times
.
In the future, the company's research and development products continue to successfully apply for listing, and it is expected that the valuation will be further improved
.